Vyriad

About:

Vyriad is a clinical stage biopharmaceutical company.

Top Investors: Regeneron, Mayo Clinic, Mirae Asset, Southeast Minnesota Capital Fund, Harry H. Stine

Description:

Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.

Total Funding Amount:

$63.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Rochester, Minnesota, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)vyriad.com

Founders:

Kah-Whye Peng, Stephen Russell

Number of Employees:

51-100

Last Funding Date:

2022-05-17

IPO Status:

Private

Industries: